POLYMER-METAL CHELATOR CONJUGATES AND USES THEREOF

• US 20090092664A1
• Filed: 10/01/2008
• Published: 04/09/2009
• Est. Priority Date: 10/08/2007
• Status: Abandoned Application

• Current Assignee: University Of Kentucky Research Foundation (University of Kentucky)
• Original Assignee: University Of Kentucky Research Foundation (University of Kentucky)
• Inventors: Gupte, Anshul, Wadhwa, Saurabh, Mumper, Russell J.
• Application Number:
  US12/243,671
• Publication Number:
  US 20090092664A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61K 47/6435 the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: C08B 11/12 substituted with carboxylic radicals , e.g. carboxymethylcellulose [CMC]
• CPC Class Codes: C08B 37/003 Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• CPC Class Codes: C08B 37/0075 Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
• CPC Class Codes: C08B 37/0084 Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
• CPC Class Codes: C08H 1/00 Macromolecular products derived from proteins food proteins A23; glue, gelatine C09H
• CPC Class Codes: C08H 1/06 derived from horn, hoofs, hair, skin or leather

Abstract

The present invention provides prodrugs comprising a polymer conjugated to a metal chelator via a disulfide bond. For example, D-penicillamine may be conjugated to a polymer (e.g., gelatin, chitosan, polyglutamic acid) via a linker, such as SPDP. Thus, the cellular delivery and pharmacokinetics of D-penicillamine can be substantially improved. Methods for the treatment of cancer using compositions of the present invention are also disclosed.

Claims

1. A composition comprising at least one D-penicillamine covalently bonded to a biocompatible polymer via a disulfide bond, wherein the disulfide bond comprises the sulfur group of D-penicillamine.

2. The composition of claim 1, wherein the polymer is gelatin.

3. The composition of claim 1, wherein the polymer is chitosan.

4. The composition of claim 1, wherein the polymer is polyglutamic acid

5. The composition of claim 1, wherein the polymer is selected from the group consisting of poly-L-lysine, poly-L-Arginine, albumin, N-(2-hydroxypropyl) methacrylamide (HPMA), polyaspartamide, a dendrimer comprising a polyamido amine and polylysine core, hyaluronic acid, polylactic-co-glycolic acid, heparin, polyacrylic acid, crosslinked polyacrylic acid, carboxymethylcellulose, alginate, alginic acid, propylene glycol alginate, sodium alginate, a polylactide, poly-glutamic acid, and polyerucic-co-sebacic acid.

6. The composition of claim 1, wherein said disulfide bond comprises a sulfur group present in the polymer, and wherein the D-penicillamine is covalently bonded directly to the polymer via the disulfide bond.

7. The composition of claim 1, wherein said disulfide bond comprises a sulfur group in a linker or a coupling agent, wherein the linker or coupling agent is covalently bonded to the polymer.

8. The composition of claim 7, wherein said linker is selected from the group consisting of SPDP, LC-SPDP, and Sulfo-LC-SPDP.

9. The composition of claim 1, wherein said polymer has at least about 20% of available functionalities occupied by D-penicillamine or a linker, wherein the linker is coupled to D-penicillamine.

10. The composition of claim 9, wherein said polymer has at least about 50% of available functionalities occupied by D-penicillamine or a linker.

11. The composition of claim 1, wherein the composition comprises gelatin-D-penicillamine.

12. The composition of claim 1, wherein the composition comprises chitosan-D-penicillamine.

13. The composition of claim 1, wherein the composition comprises polyglutamic acid-D-penicillamine.

14. The composition of claim 1, wherein the polymer is conjugated to an antibody.

15. The composition of claim 14, wherein the antibody selectively binds a protein whose expression is upregulated in a cancer.

16. The composition of claim 15, wherein the antibody is selected from the group consisting of CD123, Rituximab, Trastuzumab, Gemtuzamab, Alemtuzumab, Ibritumomab, Tositumomab, and Bevacizumab.

17. The composition of claim 1, wherein the polymer is conjugated to a polyethylene glycol having a molecular weight between about 2000 g/mol and about 20,000 g/mol.

18. The composition of claim 1, wherein the polymer is conjugated to an imaging agent.

19. The composition of claim 18, wherein the imaging agent is a fluorophore or a radioisotope.

20. The composition of claim 18, wherein the imaging agent is a photon emission computed tomography (PET) imaging agent or a single photon emission computed tomography (SPECT) imaging agent.

21. The composition of claim 1, wherein said composition is comprised in a pharmaceutically acceptable excipient.

22. The composition of claim 21, wherein said pharmaceutically acceptable excipient comprises a lipid, liposomes, or nanoparticles.

23. The composition of claim 21, wherein said pharmaceutically acceptable excipient is formulated for parenteral administration.

24. The composition of claim 23, wherein said pharmaceutically acceptable excipient is formulated for intravenous administration.

25. The composition of claim 23, wherein said pharmaceutically acceptable excipient is formulated for intratumoral injection.

26. A method of treating a cancer comprising administering a composition of claim 1 to a subject.

27. The method of claim 26, wherein said subject is a mammal.

28. The method of claim 27, wherein said mammal is a human patient.

29. The method of claim 26, wherein said composition is administered parenterally, intravenously, or intratumorally.

30. The method of claim 26, wherein said composition is administered at a dose of from about 1 microgram/kg body weight to about 1000 milligram/kg body weight.

31. The method of claim 26, wherein said method further comprises administering a second cancer therapy to the subject.

32. The method of claim 26, wherein the second cancer therapy is a chemotherapeutic, a surgery, a radiation therapy, an immunotherapy, or a gene therapy.

33. The method of claim 32, wherein said second cancer therapy is a chemotherapeutic selected from the list consisting of paclitaxel, docetaxel, doxorubicin, a platinum-containing chemotherapeutic, idarubicin, and 5-FU.

34. The method of claim 26, wherein said cancer is selected from the group consisting of leukemia, cancer of the lymph node or lymph system, bone cancer, cancer of the mouth or esophagus, stomach cancer, colon cancer, breast cancer, ovarian cancer, a gastric cancer, brain cancer, renal cancer, liver cancer, prostate cancer, melanoma, and lung cancer.